About
Iambic Therapeutics, Inc.
Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally.
It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics.
Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023.
Iambic Therapeutics, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Change from offer price to today
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:IAM
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-10-30 | $13.10 | $13.57 | $12.39 | $13.43 | $13.43 | +0.33 | 476,700 |
| 2026-10-29 | $14.79 | $14.96 | $13.76 | $14.28 | $14.28 | -0.51 | 270,100 |
| 2026-10-28 | $13.84 | $16.50 | $13.60 | $14.78 | $14.78 | +0.94 | 925,300 |
| 2026-10-27 | $14.41 | $14.90 | $13.51 | $14.00 | $14.00 | -0.41 | 439,700 |
| 2026-10-26 | $14.40 | $15.25 | $14.00 | $14.41 | $14.41 | +0.01 | 149,000 |
| 2026-10-23 | $14.50 | $14.64 | $13.02 | $14.26 | $14.26 | -0.24 | 609,600 |
| 2026-10-22 | $15.40 | $15.47 | $14.50 | $14.67 | $14.67 | -0.73 | 495,900 |
| 2026-10-21 | $15.50 | $17.06 | $15.00 | $15.80 | $15.80 | +0.30 | 478,900 |
| 2026-10-20 | $16.31 | $17.50 | $15.00 | $16.01 | $16.01 | -0.30 | 980,600 |
| 2026-10-19 | $21.00 | $21.54 | $14.10 | $16.34 | $16.34 | -4.66 | 2,382,700 |
| 2026-10-16 | $19.31 | $25.00 | $19.31 | $23.81 | $23.81 | +4.50 | 2,964,900 |
| 2026-10-15 | $16.15 | $19.70 | $16.15 | $18.91 | $18.91 | +2.76 | 2,009,400 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| 8-K | Oct 16, 2026 | Current Report |
| 424B4 | Oct 15, 2026 | Prospectus |
| S-8 | Oct 15, 2026 | Securities to be offered to employees in employee benefit plans |
| EFFECT | Oct 14, 2026 | Notice of Effectiveness |
| CERT | Oct 14, 2026 | Certification by an exchange approving securities for listing |
| 8-A12B | Oct 13, 2026 | Registration of securities |
| S-1/A | Oct 8, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| S-1 | Sep 21, 2026 | General form for registration of securities under the Securities Act of 1933 |
| D | Sep 9, 2026 | Notice of Exempt Offering of Securities |
| DRS/A | Aug 28, 2026 | [Amend] [Cover] Draft Registration Statement |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Thomas Miller, Ph.D.
Chief Executive Officer and Director
Frederick Manby, Ph.D.
Chief Technology Officer and Director
Neil Josephson, M.D.
Chief Medical Officer
Peter Olson, Ph.D.
Chief Scientific Officer
Michael Secora, Ph.D.
Chief Financial Officer and Chief Corporate Development Officer
Samit Hirawat, M.D.
Director
Evan Rachlin, M.D.
Director
William Rastetter, Ph.D.
Director
Shalini Sharp
Director
Mary Tagliaferri, M.D.
Director
